Aaron Seth Rosenberg, M.D., M.S.
Associate Professor
To see if Aaron Seth Rosenberg is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Clinic Fax
Clinic Referral Phone
Physician Referrals
Philosophy of Care
Dr. Rosenberg believes in high quality, innovative, and compassionate care of his patients. Dr. Rosenberg believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.
Clinical Interests
Dr. Rosenberg's clinical interests include the diagnosis and care of multiple myeloma, and lymphoid malignancies, as well as the management of thrombosis. He is a member of the adult hematopoietic stem cell transplant team.
Research/Academic Interests
Dr. Rosenberg focuses on outcomes research related to hematologic malignancies and thrombosis, as well as developing clinical trials for patients with hematologic malignancies.
Division
Hematology and Oncology
Malignant Hematology/Cellular Therapy and Transplantation
Center/Program Affiliation
Undergraduate School
B.A., Wesleyan University, Middletown CT 2001
Medical School
M.D., Mount Sinai School of Medicine, New York NY 2006
Other School
M.S., Sackler School of Graduate Biomedical Sciences, Tufts University, Boston MA 2014
Internship
Internal Medicine, Temple University Hospital, Philadelphia PA 2006-2009
Residency
Internal Medicine, Temple University Hospital, Philadelphia PA 2006-2009
Residency
Internal Medicine, UC San Francisco, San Francisco CA 2013-2015
Fellowship
Hematology/Oncology, Tufts Medical Center, Boston MA 2010-2013
https://ucdavis.pure.elsevier.com/en/persons/aaron-rosenberg/publications/
Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 Jan;63(1):231-234. doi:10.1080/10428194.2021.1975190. Epub 2021 Sep 6. PMID:34486920.
Whitney RL, White AEC, Rosenberg AS, Kravitz RL, Kim KK. Trust and shared decision-making among individuals with multiple myeloma: A qualitative study. Cancer Med. 2021 Nov;10(22):8040-8057. doi:10.1002/cam4.4322. Epub 2021 Oct 5. PMID:34608770.
Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E. Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clin Cancer Res. 2021 Sep 1;27(17):4726-4736. doi:10.1158/1078-0432.CCR-20-4622. Epub 2021 Jun 4. PMID:34088724.
Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e611-e618. doi:10.1016/j.clml.2021.02.007. Epub 2021 Mar 2. PMID:33811007.
Rosenberg AS, Facon T, Parikh K, Chung W, Srinivasan S, Kotey S, Tuscano J. Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):345-354.e4. doi:10.1016/j.clml.2020.12.021. Epub 2020 Dec 27. PMID:33563582.
Jonas BA, Fisch SC, Rosenberg AS, Hoeg RT, Tuscano JM, Abedi M. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2021 Apr 1;96(4):E114-E117. doi:10.1002/ajh.26105. Epub 2021 Feb 26. PMID:33476436.
Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. Front Oncol. 2021 Mar 11;11:649209. doi:10.3389/fonc.2021.649209. PMID:33777810.
Rosenberg AS, Brunson A, Tuscano J, Jonas BA, Fun T, Keegan THM. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J. 2021 Jan 7;11(5). doi:10.1038/s41408-020-00400-4.
Hoeg RT, Davis J, Jonas BA, Tuscano J, Rosenberg A, Abedi M. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):453-458. doi:10.1016/j.clml.2020.02.006. Epub 2020 Feb 20. PMID:32171691.